arrow_back Back Filing freshness 40-F Q4 FY2025 SEC EDGAR
download Export Data

Cresco Labs Inc.

CRLBF
— Price unavailable
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
6 Visible periods
5 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cresco Labs Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC —
FCF / Share —
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity 1.26
info Valuation on last close.

6-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Long-Term Debt Long-term obligations
$417.10M
↓ -9.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
26
Returns ↓
19
Financial Health ↑
34
Cash Quality ↓
15

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 6 quarters